TW200804314A - Triazole compounds that modulate Hsp90 activity - Google Patents

Info

Publication number

TW200804314A

TW200804314A TW96118673A TW96118673A TW200804314A TW 200804314 A TW200804314 A TW 200804314A TW 96118673 A TW96118673 A TW 96118673A TW 96118673 A TW96118673 A TW 96118673A TW 200804314 A TW200804314 A TW 200804314A

Authority

TW

Taiwan

Prior art keywords

optionally substituted

group

nr10rn

compound

nr7c

Prior art date

2006-05-25

Links

• Espacenet
• Global Dossier
• Discuss

• -1 Triazole compounds Chemical class 0.000 title claims abstract description 178
• 230000000694 effects Effects 0.000 title abstract description 53
• 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 title abstract description 27
• 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 title abstract description 26
• 150000001875 compounds Chemical class 0.000 claims abstract description 483
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 119
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 102
• 201000011510 cancer Diseases 0.000 claims abstract description 77
• 238000000034 method Methods 0.000 claims abstract description 34
• 239000000203 mixture Chemical class 0.000 claims abstract description 19
• 230000002401 inhibitory effect Effects 0.000 claims abstract description 11
• 125000001072 heteroaryl group Chemical group 0.000 claims description 198
• 125000000217 alkyl group Chemical group 0.000 claims description 166
• 125000000623 heterocyclic group Chemical group 0.000 claims description 151
• 125000003107 substituted aryl group Chemical group 0.000 claims description 135
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 110
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 102
• 125000000547 substituted alkyl group Chemical group 0.000 claims description 94
• 150000003839 salts Chemical class 0.000 claims description 93
• 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 85
• 125000004426 substituted alkynyl group Chemical group 0.000 claims description 84
• 229940002612 prodrug Drugs 0.000 claims description 81
• 239000000651 prodrug Substances 0.000 claims description 81
• 125000005017 substituted alkenyl group Chemical group 0.000 claims description 80
• 210000004027 cell Anatomy 0.000 claims description 79
• 239000012453 solvate Substances 0.000 claims description 78
• 229910052799 carbon Inorganic materials 0.000 claims description 73
• 125000003118 aryl group Chemical group 0.000 claims description 70
• 125000003545 alkoxy group Chemical group 0.000 claims description 69
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 67
• 239000003814 drug Substances 0.000 claims description 67
• 201000010099 disease Diseases 0.000 claims description 62
• 229910052757 nitrogen Inorganic materials 0.000 claims description 58
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 52
• 125000001424 substituent group Chemical group 0.000 claims description 51
• 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 50
• 125000001188 haloalkyl group Chemical group 0.000 claims description 46
• 108090000623 proteins and genes Proteins 0.000 claims description 43
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 42
• 238000011282 treatment Methods 0.000 claims description 42
• 150000001721 carbon Chemical group 0.000 claims description 40
• 125000004475 heteroaralkyl group Chemical group 0.000 claims description 39
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 39
• 125000004404 heteroalkyl group Chemical group 0.000 claims description 38
• 208000035475 disorder Diseases 0.000 claims description 37
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 35
• 229910003827 NRaRb Inorganic materials 0.000 claims description 32
• 108060006698 EGF receptor Proteins 0.000 claims description 31
• 125000005843 halogen group Chemical group 0.000 claims description 31
• 229940079593 drug Drugs 0.000 claims description 30
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 30
• 230000002062 proliferating effect Effects 0.000 claims description 28
• 102000004169 proteins and genes Human genes 0.000 claims description 28
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
• 241000282414 Homo sapiens Species 0.000 claims description 26
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 25
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 22
• 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 22
• 229940124597 therapeutic agent Drugs 0.000 claims description 22
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 21
• 206010036790 Productive cough Diseases 0.000 claims description 20
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 20
• 208000015181 infectious disease Diseases 0.000 claims description 20
• 229910052701 rubidium Inorganic materials 0.000 claims description 20
• 210000003802 sputum Anatomy 0.000 claims description 20
• 208000024794 sputum Diseases 0.000 claims description 20
• 125000003396 thiol group Chemical group [H]S* 0.000 claims description 20
• 125000003342 alkenyl group Chemical group 0.000 claims description 19
• 125000003282 alkyl amino group Chemical group 0.000 claims description 19
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 19
• 229910052705 radium Inorganic materials 0.000 claims description 19
• 239000000126 substance Substances 0.000 claims description 18
• 125000004438 haloalkoxy group Chemical group 0.000 claims description 17
• 125000005842 heteroatom Chemical group 0.000 claims description 17
• 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 17
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 17
• 108091008648 NR7C Proteins 0.000 claims description 16
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 16
• 229910052739 hydrogen Inorganic materials 0.000 claims description 16
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 15
• 150000001412 amines Chemical class 0.000 claims description 15
• 230000002265 prevention Effects 0.000 claims description 15
• 125000004432 carbon atom Chemical group C* 0.000 claims description 14
• 230000015556 catabolic process Effects 0.000 claims description 14
• 238000006731 degradation reaction Methods 0.000 claims description 14
• 125000004076 pyridyl group Chemical group 0.000 claims description 14
• 206010025323 Lymphomas Diseases 0.000 claims description 13
• 125000004429 atom Chemical group 0.000 claims description 13
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 13
• 241000124008 Mammalia Species 0.000 claims description 12
• 125000004663 dialkyl amino group Chemical group 0.000 claims description 12
• 239000001257 hydrogen Substances 0.000 claims description 12
• 230000001105 regulatory effect Effects 0.000 claims description 12
• 239000002253 acid Substances 0.000 claims description 11
• 125000000304 alkynyl group Chemical group 0.000 claims description 11
• 125000003277 amino group Chemical group 0.000 claims description 11
• 230000005764 inhibitory process Effects 0.000 claims description 11
• 229910052717 sulfur Inorganic materials 0.000 claims description 11
• NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 10
• 239000013078 crystal Substances 0.000 claims description 10
• 238000004519 manufacturing process Methods 0.000 claims description 10
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 10
• AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 9
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims description 9
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims description 9
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 9
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
• 229910052760 oxygen Inorganic materials 0.000 claims description 9
• 239000001301 oxygen Substances 0.000 claims description 9
• 210000000987 immune system Anatomy 0.000 claims description 8
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
• KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 7
• 101100516572 Caenorhabditis elegans nhr-8 gene Proteins 0.000 claims description 7
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
• 125000000000 cycloalkoxy group Chemical group 0.000 claims description 7
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 7
• 125000005265 dialkylamine group Chemical group 0.000 claims description 7
• 150000002431 hydrogen Chemical class 0.000 claims description 7
• 229910052707 ruthenium Inorganic materials 0.000 claims description 7
• 239000002689 soil Substances 0.000 claims description 7
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
• 150000003852 triazoles Chemical class 0.000 claims description 7
• 230000002792 vascular Effects 0.000 claims description 7
• 102000004190 Enzymes Human genes 0.000 claims description 6
• 108090000790 Enzymes Proteins 0.000 claims description 6
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 6
• KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 6
• 125000002947 alkylene group Chemical group 0.000 claims description 6
• 230000015572 biosynthetic process Effects 0.000 claims description 6
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
• 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 claims description 6
• 230000003412 degenerative effect Effects 0.000 claims description 6
• 239000007789 gas Substances 0.000 claims description 6
• 208000027866 inflammatory disease Diseases 0.000 claims description 6
• 150000002576 ketones Chemical class 0.000 claims description 6
• 208000003747 lymphoid leukemia Diseases 0.000 claims description 6
• 230000009385 viral infection Effects 0.000 claims description 6
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 5
• 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 claims description 5
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 5
• 241001465754 Metazoa Species 0.000 claims description 5
• 239000005864 Sulphur Substances 0.000 claims description 5
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
• 208000036142 Viral infection Diseases 0.000 claims description 5
• 150000001241 acetals Chemical class 0.000 claims description 5
• 230000000903 blocking effect Effects 0.000 claims description 5
• 125000004122 cyclic group Chemical group 0.000 claims description 5
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 5
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 5
• 150000003254 radicals Chemical class 0.000 claims description 5
• 239000004575 stone Substances 0.000 claims description 5
• 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
• 239000007983 Tris buffer Substances 0.000 claims description 4
• DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 4
• 230000017531 blood circulation Effects 0.000 claims description 4
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 125000000524 functional group Chemical group 0.000 claims description 4
• 229910052736 halogen Inorganic materials 0.000 claims description 4
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
• 210000001165 lymph node Anatomy 0.000 claims description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims description 4
• ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 4
• 201000006845 reticulosarcoma Diseases 0.000 claims description 4
• 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 4
• 239000011593 sulfur Substances 0.000 claims description 4
• SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 claims description 4
• 208000035143 Bacterial infection Diseases 0.000 claims description 3
• 208000011691 Burkitt lymphomas Diseases 0.000 claims description 3
• 241000196324 Embryophyta Species 0.000 claims description 3
• 206010017533 Fungal infection Diseases 0.000 claims description 3
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 3
• 208000031888 Mycoses Diseases 0.000 claims description 3
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
• 208000007452 Plasmacytoma Diseases 0.000 claims description 3
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
• 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 3
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 3
• 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
• 238000002425 crystallisation Methods 0.000 claims description 3
• 230000008025 crystallization Effects 0.000 claims description 3
• 150000001925 cycloalkenes Chemical class 0.000 claims description 3
• 201000003444 follicular lymphoma Diseases 0.000 claims description 3
• 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims description 3
• 239000000463 material Substances 0.000 claims description 3
• 125000001624 naphthyl group Chemical group 0.000 claims description 3
• 150000002923 oximes Chemical class 0.000 claims description 3
• 210000003296 saliva Anatomy 0.000 claims description 3
• 125000005415 substituted alkoxy group Chemical group 0.000 claims description 3
• 238000012360 testing method Methods 0.000 claims description 3
• 125000000335 thiazolyl group Chemical group 0.000 claims description 3
• XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 claims description 2
• 150000004057 1,4-benzoquinones Chemical class 0.000 claims description 2
• 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
• 150000003973 alkyl amines Chemical class 0.000 claims description 2
• HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims description 2
• 230000000747 cardiac effect Effects 0.000 claims description 2
• 230000008859 change Effects 0.000 claims description 2
• 125000000068 chlorophenyl group Chemical group 0.000 claims description 2
• 238000003776 cleavage reaction Methods 0.000 claims description 2
• 239000000839 emulsion Substances 0.000 claims description 2
• BFUDIOUIRIFFPV-UHFFFAOYSA-N ethyl [5-[2,4-bis(ethoxycarbonyloxy)phenyl]-4-naphthalen-1-yl-1,2,4-triazol-3-yl]sulfanylformate Chemical compound CCOC(=O)OC1=CC(OC(=O)OCC)=CC=C1C1=NN=C(SC(=O)OCC)N1C1=CC=CC2=CC=CC=C12 BFUDIOUIRIFFPV-UHFFFAOYSA-N 0.000 claims description 2
• 125000005647 linker group Chemical group 0.000 claims description 2
• 201000011649 lymphoblastic lymphoma Diseases 0.000 claims description 2
• 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 2
• 208000021937 marginal zone lymphoma Diseases 0.000 claims description 2
• 230000008774 maternal effect Effects 0.000 claims description 2
• PLXPTFQGYWXIEA-UHFFFAOYSA-N nitroformonitrile Chemical compound [O-][N+](=O)C#N PLXPTFQGYWXIEA-UHFFFAOYSA-N 0.000 claims description 2
• 230000007017 scission Effects 0.000 claims description 2
• 125000004414 alkyl thio group Chemical group 0.000 claims 17
• 238000002360 preparation method Methods 0.000 claims 14
• RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 8
• 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 claims 8
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 6
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 5
• 150000003573 thiols Chemical class 0.000 claims 5
• ZCQWOFVYLHDMMC-UHFFFAOYSA-O hydron;1,3-oxazole Chemical class C1=COC=[NH+]1 ZCQWOFVYLHDMMC-UHFFFAOYSA-O 0.000 claims 4
• 229960001755 resorcinol Drugs 0.000 claims 4
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 3
• 125000004448 alkyl carbonyl group Chemical group 0.000 claims 3
• 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 3
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims 3
• 229910052805 deuterium Inorganic materials 0.000 claims 3
• 150000002367 halogens Chemical class 0.000 claims 3
• 230000001939 inductive effect Effects 0.000 claims 3
• 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 3
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
• KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 claims 2
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
• QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
• 125000002355 alkine group Chemical group 0.000 claims 2
• 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 2
• 229940037003 alum Drugs 0.000 claims 2
• 125000006612 decyloxy group Chemical group 0.000 claims 2
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
• 150000004702 methyl esters Chemical class 0.000 claims 2
• YCIMNLLNPGFGHC-UHFFFAOYSA-N o-dihydroxy-benzene Natural products OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims 2
• FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 claims 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims 2
• 125000001725 pyrenyl group Chemical group 0.000 claims 2
• GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims 2
• 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 1
• LZTSCEYDCZBRCJ-UHFFFAOYSA-N 1,2-dihydro-1,2,4-triazol-3-one Chemical compound OC=1N=CNN=1 LZTSCEYDCZBRCJ-UHFFFAOYSA-N 0.000 claims 1
• SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 claims 1
• GPLIMIJPIZGPIF-UHFFFAOYSA-N 2-hydroxy-1,4-benzoquinone Chemical compound OC1=CC(=O)C=CC1=O GPLIMIJPIZGPIF-UHFFFAOYSA-N 0.000 claims 1
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
• BFJMHTOBRRZELQ-UHFFFAOYSA-N 3-iodo-2h-pyrazolo[3,4-c]pyridine Chemical group N1=CC=C2C(I)=NNC2=C1 BFJMHTOBRRZELQ-UHFFFAOYSA-N 0.000 claims 1
• SIPOCSQFZLASGF-UHFFFAOYSA-N 3-methyl-2,2-bis[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(C)C)(NC(=O)OC(C)(C)C)C(O)=O SIPOCSQFZLASGF-UHFFFAOYSA-N 0.000 claims 1
• XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 claims 1
• CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 claims 1
• OGZSTOMGSUXMHB-UHFFFAOYSA-N 5-(sulfamoylamino)-1H-1,2,4-triazole Chemical compound NS(=O)(=O)NC=1N=CNN=1 OGZSTOMGSUXMHB-UHFFFAOYSA-N 0.000 claims 1
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 1
• KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 claims 1
• 101100439665 Arabidopsis thaliana SWI2 gene Proteins 0.000 claims 1
• BQLWULUILVXKCH-UHFFFAOYSA-N C(C)(C)C1=CC=CC=C1.N1C=CC2=CC=CC=C12 Chemical compound C(C)(C)C1=CC=CC=C1.N1C=CC2=CC=CC=C12 BQLWULUILVXKCH-UHFFFAOYSA-N 0.000 claims 1
• YPGHUZUVJDFFGV-UHFFFAOYSA-N C1(C=CC(C=C1)=O)=O.C1=CC=CC=2C3=CC=CC=C3CC12 Chemical compound C1(C=CC(C=C1)=O)=O.C1=CC=CC=2C3=CC=CC=C3CC12 YPGHUZUVJDFFGV-UHFFFAOYSA-N 0.000 claims 1
• LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 1
• BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical compound C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 claims 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
• 244000166124 Eucalyptus globulus Species 0.000 claims 1
• RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 claims 1
• 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
• 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 claims 1
• 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims 1
• 244000046052 Phaseolus vulgaris Species 0.000 claims 1
• 235000010627 Phaseolus vulgaris Nutrition 0.000 claims 1
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
• SZKKRCSOSQAJDE-UHFFFAOYSA-N Schradan Chemical group CN(C)P(=O)(N(C)C)OP(=O)(N(C)C)N(C)C SZKKRCSOSQAJDE-UHFFFAOYSA-N 0.000 claims 1
• 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 claims 1
• 208000033809 Suppuration Diseases 0.000 claims 1
• 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims 1
• 241000534944 Thia Species 0.000 claims 1
• 150000001345 alkine derivatives Chemical class 0.000 claims 1
• 125000003418 alkyl amino alkoxy group Chemical group 0.000 claims 1
• 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 1
• 150000001356 alkyl thiols Chemical class 0.000 claims 1
• XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims 1
• 229910052786 argon Inorganic materials 0.000 claims 1
• 150000001485 argon Chemical class 0.000 claims 1
• 125000005334 azaindolyl group Chemical class N1N=C(C2=CC=CC=C12)* 0.000 claims 1
• 239000012964 benzotriazole Substances 0.000 claims 1
• 125000003354 benzotriazolyl group Chemical class N1N=NC2=C1C=CC=C2* 0.000 claims 1
• 239000004305 biphenyl Substances 0.000 claims 1
• CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 claims 1
• 229960005286 carbaryl Drugs 0.000 claims 1
• 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
• 150000001768 cations Chemical class 0.000 claims 1
• 230000000739 chaotic effect Effects 0.000 claims 1
• 229940125904 compound 1 Drugs 0.000 claims 1
• 239000000470 constituent Substances 0.000 claims 1
• 230000000593 degrading effect Effects 0.000 claims 1
• 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 1
• 125000004984 dialkylaminoalkoxy group Chemical group 0.000 claims 1
• UOUXNEHTZXMGSV-UHFFFAOYSA-N dimethylaminocarbamic acid Chemical compound CN(C)NC(O)=O UOUXNEHTZXMGSV-UHFFFAOYSA-N 0.000 claims 1
• 150000002009 diols Chemical class 0.000 claims 1
• 235000013399 edible fruits Nutrition 0.000 claims 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
• TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 claims 1
• 125000005549 heteroarylene group Chemical group 0.000 claims 1
• 150000004693 imidazolium salts Chemical class 0.000 claims 1
• 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
• VTWDKFNVVLAELH-UHFFFAOYSA-N methyl-p-benzoquinone Natural products CC1=CC(=O)C=CC1=O VTWDKFNVVLAELH-UHFFFAOYSA-N 0.000 claims 1
• 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
• 239000008267 milk Substances 0.000 claims 1
• 239000002324 mouth wash Substances 0.000 claims 1
• 229940051866 mouthwash Drugs 0.000 claims 1
• 125000006611 nonyloxy group Chemical group 0.000 claims 1
• 125000003544 oxime group Chemical group 0.000 claims 1
• 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 claims 1
• JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical group C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims 1
• 125000003884 phenylalkyl group Chemical group 0.000 claims 1
• HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical group NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 claims 1
• 229940067157 phenylhydrazine Drugs 0.000 claims 1
• AFDMODCXODAXLC-UHFFFAOYSA-N phenylmethanimine Chemical compound N=CC1=CC=CC=C1 AFDMODCXODAXLC-UHFFFAOYSA-N 0.000 claims 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
• 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
• 239000000243 solution Substances 0.000 claims 1
• 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims 1
• 229960000368 sulisobenzone Drugs 0.000 claims 1
• 239000000454 talc Substances 0.000 claims 1
• 229910052623 talc Inorganic materials 0.000 claims 1
• FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 claims 1
• 125000003831 tetrazolyl group Chemical group 0.000 claims 1
• 150000003648 triterpenes Chemical class 0.000 claims 1
• 239000000052 vinegar Substances 0.000 claims 1
• 235000021419 vinegar Nutrition 0.000 claims 1
• 230000000007 visual effect Effects 0.000 claims 1
• 230000003463 hyperproliferative effect Effects 0.000 abstract description 4
• 230000035772 mutation Effects 0.000 description 60
• 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 41
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 41
• 239000002585 base Substances 0.000 description 41
• 102000001301 EGF receptor Human genes 0.000 description 31
• KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 28
• 101100381978 Mus musculus Braf gene Proteins 0.000 description 28
• 235000018102 proteins Nutrition 0.000 description 26
• 108091000080 Phosphotransferase Proteins 0.000 description 25
• 208000032839 leukemia Diseases 0.000 description 25
• 102000020233 phosphotransferase Human genes 0.000 description 25
• 239000002246 antineoplastic agent Substances 0.000 description 21
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 20
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 20
• 238000002560 therapeutic procedure Methods 0.000 description 19
• 230000003213 activating effect Effects 0.000 description 16
• 210000004369 blood Anatomy 0.000 description 16
• 239000008280 blood Substances 0.000 description 16
• 208000024891 symptom Diseases 0.000 description 16
• 230000004913 activation Effects 0.000 description 15
• 230000027455 binding Effects 0.000 description 13
• 230000001684 chronic effect Effects 0.000 description 13
• 230000026731 phosphorylation Effects 0.000 description 13
• 238000006366 phosphorylation reaction Methods 0.000 description 13
• 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 12
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 12
• 208000023275 Autoimmune disease Diseases 0.000 description 12
• 206010061218 Inflammation Diseases 0.000 description 12
• 230000004054 inflammatory process Effects 0.000 description 12
• 239000012528 membrane Substances 0.000 description 12
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 12
• 102000005962 receptors Human genes 0.000 description 12
• 108020003175 receptors Proteins 0.000 description 12
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 11
• 206010006187 Breast cancer Diseases 0.000 description 11
• 208000026310 Breast neoplasm Diseases 0.000 description 11
• 102100021866 Hepatocyte growth factor Human genes 0.000 description 11
• 208000005718 Stomach Neoplasms Diseases 0.000 description 11
• 206010017758 gastric cancer Diseases 0.000 description 11
• 230000001965 increasing effect Effects 0.000 description 11
• 201000011549 stomach cancer Diseases 0.000 description 11
• 230000004083 survival effect Effects 0.000 description 11
• 210000001519 tissue Anatomy 0.000 description 11
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 10
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 10
• 206010039491 Sarcoma Diseases 0.000 description 10
• 241000700605 Viruses Species 0.000 description 10
• 125000000539 amino acid group Chemical group 0.000 description 10
• 230000004663 cell proliferation Effects 0.000 description 10
• 238000011161 development Methods 0.000 description 10
• 230000018109 developmental process Effects 0.000 description 10
• 230000014509 gene expression Effects 0.000 description 10
• 210000004379 membrane Anatomy 0.000 description 10
• 230000002018 overexpression Effects 0.000 description 10
• 230000037361 pathway Effects 0.000 description 10
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 9
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 9
• 206010041067 Small cell lung cancer Diseases 0.000 description 9
• 230000001154 acute effect Effects 0.000 description 9
• 235000001014 amino acid Nutrition 0.000 description 9
• 229940127089 cytotoxic agent Drugs 0.000 description 9
• 230000004968 inflammatory condition Effects 0.000 description 9
• 230000002757 inflammatory effect Effects 0.000 description 9
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 9
• 230000000069 prophylactic effect Effects 0.000 description 9
• 102000016914 ras Proteins Human genes 0.000 description 9
• 208000000587 small cell lung carcinoma Diseases 0.000 description 9
• 208000011580 syndromic disease Diseases 0.000 description 9
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 9
• 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 8
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 8
• 206010009944 Colon cancer Diseases 0.000 description 8
• 239000003795 chemical substances by application Substances 0.000 description 8
• 102000037865 fusion proteins Human genes 0.000 description 8
• 108020001507 fusion proteins Proteins 0.000 description 8
• 230000012010 growth Effects 0.000 description 8
• 229920006395 saturated elastomer Polymers 0.000 description 8
• 210000003491 skin Anatomy 0.000 description 8
• 206010018338 Glioma Diseases 0.000 description 7
• 241000222722 Leishmania <genus> Species 0.000 description 7
• 108700020796 Oncogene Proteins 0.000 description 7
• 206010033128 Ovarian cancer Diseases 0.000 description 7
• 206010061535 Ovarian neoplasm Diseases 0.000 description 7
• 230000002159 abnormal effect Effects 0.000 description 7
• 150000001413 amino acids Chemical class 0.000 description 7
• 238000006243 chemical reaction Methods 0.000 description 7
• 210000000349 chromosome Anatomy 0.000 description 7
• 239000003446 ligand Substances 0.000 description 7
• 102200055464 rs113488022 Human genes 0.000 description 7
• 230000019491 signal transduction Effects 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 6
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 6
• 102000003676 Glucocorticoid Receptors Human genes 0.000 description 6
• 108090000079 Glucocorticoid Receptors Proteins 0.000 description 6
• 102000043136 MAP kinase family Human genes 0.000 description 6
• 108091054455 MAP kinase family Proteins 0.000 description 6
• 102100040243 Microtubule-associated protein tau Human genes 0.000 description 6
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 6
• 230000033115 angiogenesis Effects 0.000 description 6
• 238000002512 chemotherapy Methods 0.000 description 6
• 208000029742 colonic neoplasm Diseases 0.000 description 6
• 238000006471 dimerization reaction Methods 0.000 description 6
• 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 6
• 108700021358 erbB-1 Genes Proteins 0.000 description 6
• 150000002148 esters Chemical class 0.000 description 6
• 206010020718 hyperplasia Diseases 0.000 description 6
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 6
• 208000026278 immune system disease Diseases 0.000 description 6
• 230000001976 improved effect Effects 0.000 description 6
• 201000006747 infectious mononucleosis Diseases 0.000 description 6
• 208000025113 myeloid leukemia Diseases 0.000 description 6
• 210000000056 organ Anatomy 0.000 description 6
• 238000010837 poor prognosis Methods 0.000 description 6
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 6
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 6
• ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 6
• 229960000885 rifabutin Drugs 0.000 description 6
• AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 6
• 229950007866 tanespimycin Drugs 0.000 description 6
• 230000009466 transformation Effects 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 206010027654 Allergic conditions Diseases 0.000 description 5
• 241000894006 Bacteria Species 0.000 description 5
• 208000005623 Carcinogenesis Diseases 0.000 description 5
• 101150039808 Egfr gene Proteins 0.000 description 5
• 208000032612 Glial tumor Diseases 0.000 description 5
• 208000017604 Hodgkin disease Diseases 0.000 description 5
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 5
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 5
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 5
• 206010024305 Leukaemia monocytic Diseases 0.000 description 5
• 101150105382 MET gene Proteins 0.000 description 5
• 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 5
• 230000003321 amplification Effects 0.000 description 5
• 229940124650 anti-cancer therapies Drugs 0.000 description 5
• 238000011319 anticancer therapy Methods 0.000 description 5
• 229940041181 antineoplastic drug Drugs 0.000 description 5
• 230000006907 apoptotic process Effects 0.000 description 5
• 230000036952 cancer formation Effects 0.000 description 5
• 231100000504 carcinogenesis Toxicity 0.000 description 5
• 229940088598 enzyme Drugs 0.000 description 5
• 230000002008 hemorrhagic effect Effects 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 206010025135 lupus erythematosus Diseases 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 201000006894 monocytic leukemia Diseases 0.000 description 5
• 238000003199 nucleic acid amplification method Methods 0.000 description 5
• 239000012071 phase Substances 0.000 description 5
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 206010039073 rheumatoid arthritis Diseases 0.000 description 5
• 239000002904 solvent Substances 0.000 description 5
• 230000000087 stabilizing effect Effects 0.000 description 5
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
• 230000005945 translocation Effects 0.000 description 5
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
• 206010000830 Acute leukaemia Diseases 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 208000004736 B-Cell Leukemia Diseases 0.000 description 4
• 201000009030 Carcinoma Diseases 0.000 description 4
• 201000004624 Dermatitis Diseases 0.000 description 4
• 201000009273 Endometriosis Diseases 0.000 description 4
• 241000588724 Escherichia coli Species 0.000 description 4
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 4
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 208000007766 Kaposi sarcoma Diseases 0.000 description 4
• 108010044023 Ki-1 Antigen Proteins 0.000 description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
• 206010027476 Metastases Diseases 0.000 description 4
• 241000235648 Pichia Species 0.000 description 4
• 206010060862 Prostate cancer Diseases 0.000 description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
• 201000004681 Psoriasis Diseases 0.000 description 4
• 208000006265 Renal cell carcinoma Diseases 0.000 description 4
• 241000235070 Saccharomyces Species 0.000 description 4
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
• 208000000389 T-cell leukemia Diseases 0.000 description 4
• 102000040945 Transcription factor Human genes 0.000 description 4
• 108091023040 Transcription factor Proteins 0.000 description 4
• 206010052779 Transplant rejections Diseases 0.000 description 4
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 4
• 208000025865 Ulcer Diseases 0.000 description 4
• 208000009956 adenocarcinoma Diseases 0.000 description 4
• 208000010668 atopic eczema Diseases 0.000 description 4
• 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 4
• 102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 4
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
• 210000004204 blood vessel Anatomy 0.000 description 4
• 230000006378 damage Effects 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 108700014844 flt3 ligand Proteins 0.000 description 4
• 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 4
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
• 229940071870 hydroiodic acid Drugs 0.000 description 4
• 229960002411 imatinib Drugs 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 206010023332 keratitis Diseases 0.000 description 4
• 201000007270 liver cancer Diseases 0.000 description 4
• 208000014018 liver neoplasm Diseases 0.000 description 4
• 201000005202 lung cancer Diseases 0.000 description 4
• 208000020816 lung neoplasm Diseases 0.000 description 4
• 238000012423 maintenance Methods 0.000 description 4
• 230000036210 malignancy Effects 0.000 description 4
• 230000003211 malignant effect Effects 0.000 description 4
• 201000001441 melanoma Diseases 0.000 description 4
• 230000009401 metastasis Effects 0.000 description 4
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
• 108090000765 processed proteins & peptides Proteins 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 125000006239 protecting group Chemical group 0.000 description 4
• 230000009257 reactivity Effects 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 230000035939 shock Effects 0.000 description 4
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
• 231100000397 ulcer Toxicity 0.000 description 4
• NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 3
• VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 3
• FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• 101150049556 Bcr gene Proteins 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 241000722885 Brettanomyces Species 0.000 description 3
• 101100450705 Caenorhabditis elegans hif-1 gene Proteins 0.000 description 3
• 241000282465 Canis Species 0.000 description 3
• 206010009900 Colitis ulcerative Diseases 0.000 description 3
• 208000011231 Crohn disease Diseases 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 108020004414 DNA Proteins 0.000 description 3
• 206010012689 Diabetic retinopathy Diseases 0.000 description 3
• BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
• 102000009465 Growth Factor Receptors Human genes 0.000 description 3
• 108010009202 Growth Factor Receptors Proteins 0.000 description 3
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• 206010021143 Hypoxia Diseases 0.000 description 3
• 208000008839 Kidney Neoplasms Diseases 0.000 description 3
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 3
• 208000019693 Lung disease Diseases 0.000 description 3
• 241000555688 Malassezia furfur Species 0.000 description 3
• 208000034578 Multiple myelomas Diseases 0.000 description 3
• 241001529936 Murinae Species 0.000 description 3
• 102100022678 Nucleophosmin Human genes 0.000 description 3
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
• 208000030852 Parasitic disease Diseases 0.000 description 3
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
• 102000004422 Phospholipase C gamma Human genes 0.000 description 3
• 108010056751 Phospholipase C gamma Proteins 0.000 description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 description 3
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001253 Protein Kinase Human genes 0.000 description 3
• 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 3
• 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 3
• 206010039710 Scleroderma Diseases 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 3
• 208000024313 Testicular Neoplasms Diseases 0.000 description 3
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• 208000024770 Thyroid neoplasm Diseases 0.000 description 3
• 102400001320 Transforming growth factor alpha Human genes 0.000 description 3
• 101800004564 Transforming growth factor alpha Proteins 0.000 description 3
• 201000006704 Ulcerative Colitis Diseases 0.000 description 3
• 206010046851 Uveitis Diseases 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 3
• 208000006673 asthma Diseases 0.000 description 3
• 210000003719 b-lymphocyte Anatomy 0.000 description 3
• 125000005605 benzo group Chemical group 0.000 description 3
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
• 230000003115 biocidal effect Effects 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 210000001185 bone marrow Anatomy 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 206010006451 bronchitis Diseases 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 230000024245 cell differentiation Effects 0.000 description 3
• 230000010261 cell growth Effects 0.000 description 3
• 208000006990 cholangiocarcinoma Diseases 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 230000037011 constitutive activity Effects 0.000 description 3
• 230000007850 degeneration Effects 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 230000004927 fusion Effects 0.000 description 3
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 210000004907 gland Anatomy 0.000 description 3
• 239000003102 growth factor Substances 0.000 description 3
• 230000003394 haemopoietic effect Effects 0.000 description 3
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 3
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
• 229930195733 hydrocarbon Natural products 0.000 description 3
• 150000004679 hydroxides Chemical class 0.000 description 3
• 230000001969 hypertrophic effect Effects 0.000 description 3
• 230000036737 immune function Effects 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 201000001371 inclusion conjunctivitis Diseases 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 208000014674 injury Diseases 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
• 201000006417 multiple sclerosis Diseases 0.000 description 3
• 201000008383 nephritis Diseases 0.000 description 3
• 102000027450 oncoproteins Human genes 0.000 description 3
• 108091008819 oncoproteins Proteins 0.000 description 3
• 230000020477 pH reduction Effects 0.000 description 3
• 201000002528 pancreatic cancer Diseases 0.000 description 3
• 208000008443 pancreatic carcinoma Diseases 0.000 description 3
• 201000010279 papillary renal cell carcinoma Diseases 0.000 description 3
• 210000004214 philadelphia chromosome Anatomy 0.000 description 3
• 125000003367 polycyclic group Chemical group 0.000 description 3
• 238000004393 prognosis Methods 0.000 description 3
• 108060006633 protein kinase Proteins 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 208000016691 refractory malignant neoplasm Diseases 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 210000002784 stomach Anatomy 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 201000003120 testicular cancer Diseases 0.000 description 3
• 201000002510 thyroid cancer Diseases 0.000 description 3
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
• 206010044325 trachoma Diseases 0.000 description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
• 230000029663 wound healing Effects 0.000 description 3
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
• AFFLGGQVNFXPEV-UHFFFAOYSA-N 1-decene Chemical compound CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 2
• WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 241000224422 Acanthamoeba Species 0.000 description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
• 241000224489 Amoeba Species 0.000 description 2
• 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• 206010003645 Atopy Diseases 0.000 description 2
• 241000223836 Babesia Species 0.000 description 2
• 206010005003 Bladder cancer Diseases 0.000 description 2
• 244000027711 Brettanomyces bruxellensis Species 0.000 description 2
• 206010006448 Bronchiolitis Diseases 0.000 description 2
• 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
• 241000222178 Candida tropicalis Species 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 239000004215 Carbon black (E152) Substances 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• 208000035473 Communicable disease Diseases 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• 230000004544 DNA amplification Effects 0.000 description 2
• 241000235036 Debaryomyces hansenii Species 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• 206010058314 Dysplasia Diseases 0.000 description 2
• 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
• 208000004232 Enteritis Diseases 0.000 description 2
• 102400001368 Epidermal growth factor Human genes 0.000 description 2
• 101800003838 Epidermal growth factor Proteins 0.000 description 2
• 206010015150 Erythema Diseases 0.000 description 2
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
• 102100038595 Estrogen receptor Human genes 0.000 description 2
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• 206010016654 Fibrosis Diseases 0.000 description 2
• 208000004262 Food Hypersensitivity Diseases 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
• JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 2
• 206010064571 Gene mutation Diseases 0.000 description 2
• 208000034951 Genetic Translocation Diseases 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
• 102100026973 Heat shock protein 75 kDa, mitochondrial Human genes 0.000 description 2
• 102220553470 Hepatocyte growth factor receptor_Y1230C_mutation Human genes 0.000 description 2
• 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 2
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
• 206010020649 Hyperkeratosis Diseases 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 108060003951 Immunoglobulin Proteins 0.000 description 2
• 206010062016 Immunosuppression Diseases 0.000 description 2
• 208000006877 Insect Bites and Stings Diseases 0.000 description 2
• 241000710842 Japanese encephalitis virus Species 0.000 description 2
• 208000001126 Keratosis Diseases 0.000 description 2
• 206010023421 Kidney fibrosis Diseases 0.000 description 2
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
• 206010023927 Lassa fever Diseases 0.000 description 2
• 208000016604 Lyme disease Diseases 0.000 description 2
• 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
• 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
• 201000005505 Measles Diseases 0.000 description 2
• 201000009906 Meningitis Diseases 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• 206010048723 Multiple-drug resistance Diseases 0.000 description 2
• 206010062207 Mycobacterial infection Diseases 0.000 description 2
• 206010029113 Neovascularisation Diseases 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• 208000009905 Neurofibromatoses Diseases 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 208000000474 Poliomyelitis Diseases 0.000 description 2
• 241001505332 Polyomavirus sp. Species 0.000 description 2
• 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 108091008611 Protein Kinase B Proteins 0.000 description 2
• 201000002154 Pterygium Diseases 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 2
• 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 2
• 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 2
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 208000017442 Retinal disease Diseases 0.000 description 2
• 206010038923 Retinopathy Diseases 0.000 description 2
• 241000223252 Rhodotorula Species 0.000 description 2
• 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 2
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
• 206010057644 Testis cancer Diseases 0.000 description 2
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
• 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 2
• 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• 241000607734 Yersinia <bacteria> Species 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 208000004064 acoustic neuroma Diseases 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
• 239000013566 allergen Substances 0.000 description 2
• 230000000172 allergic effect Effects 0.000 description 2
• 125000003275 alpha amino acid group Chemical group 0.000 description 2
• 238000002399 angioplasty Methods 0.000 description 2
• 238000011203 antimicrobial therapy Methods 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 244000309743 astrovirus Species 0.000 description 2
• 201000008937 atopic dermatitis Diseases 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 230000035578 autophosphorylation Effects 0.000 description 2
• 201000008680 babesiosis Diseases 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
• 229940092714 benzenesulfonic acid Drugs 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 210000002798 bone marrow cell Anatomy 0.000 description 2
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 230000022131 cell cycle Effects 0.000 description 2
• 230000025084 cell cycle arrest Effects 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 230000012292 cell migration Effects 0.000 description 2
• 230000010307 cell transformation Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 201000007455 central nervous system cancer Diseases 0.000 description 2
• 230000002490 cerebral effect Effects 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 208000024207 chronic leukemia Diseases 0.000 description 2
• 208000019425 cirrhosis of liver Diseases 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 230000006552 constitutive activation Effects 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 230000008482 dysregulation Effects 0.000 description 2
• 229940121647 egfr inhibitor Drugs 0.000 description 2
• 229940116977 epidermal growth factor Drugs 0.000 description 2
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 201000004101 esophageal cancer Diseases 0.000 description 2
• 108010038795 estrogen receptors Proteins 0.000 description 2
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
• 206010016256 fatigue Diseases 0.000 description 2
• 210000005002 female reproductive tract Anatomy 0.000 description 2
• 206010016629 fibroma Diseases 0.000 description 2
• 235000020932 food allergy Nutrition 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 208000007565 gingivitis Diseases 0.000 description 2
• 229940080856 gleevec Drugs 0.000 description 2
• 238000005469 granulation Methods 0.000 description 2
• 230000003179 granulation Effects 0.000 description 2
• 235000015220 hamburgers Nutrition 0.000 description 2
• 210000003128 head Anatomy 0.000 description 2
• 201000011066 hemangioma Diseases 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• 231100000283 hepatitis Toxicity 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 230000001146 hypoxic effect Effects 0.000 description 2
• 102000018358 immunoglobulin Human genes 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 229940084651 iressa Drugs 0.000 description 2
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
• 201000010666 keratoconjunctivitis Diseases 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 229940043355 kinase inhibitor Drugs 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 102000006240 membrane receptors Human genes 0.000 description 2
• 108020004084 membrane receptors Proteins 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 229960005181 morphine Drugs 0.000 description 2
• 208000027531 mycobacterial infectious disease Diseases 0.000 description 2
• 210000000066 myeloid cell Anatomy 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 208000007538 neurilemmoma Diseases 0.000 description 2
• 201000004931 neurofibromatosis Diseases 0.000 description 2
• 125000004433 nitrogen atom Chemical group N* 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• 230000000414 obstructive effect Effects 0.000 description 2
• 201000008968 osteosarcoma Diseases 0.000 description 2
• 125000004430 oxygen atom Chemical group O* 0.000 description 2
• 244000045947 parasite Species 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 208000028169 periodontal disease Diseases 0.000 description 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 230000002085 persistent effect Effects 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
• 229910052697 platinum Inorganic materials 0.000 description 2
• 108050009312 plexin Proteins 0.000 description 2
• 102000002022 plexin Human genes 0.000 description 2
• 201000011461 pre-eclampsia Diseases 0.000 description 2
• 230000003449 preventive effect Effects 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 102000003998 progesterone receptors Human genes 0.000 description 2
• 108090000468 progesterone receptors Proteins 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 208000005069 pulmonary fibrosis Diseases 0.000 description 2
• 230000025053 regulation of cell proliferation Effects 0.000 description 2
• 230000000241 respiratory effect Effects 0.000 description 2
• 208000023504 respiratory system disease Diseases 0.000 description 2
• 208000037803 restenosis Diseases 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 102200014493 rs121909124 Human genes 0.000 description 2
• 102200055529 rs121913351 Human genes 0.000 description 2
• 102200055532 rs121913355 Human genes 0.000 description 2
• 102200055469 rs121913377 Human genes 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 206010039667 schwannoma Diseases 0.000 description 2
• 208000012201 sexual and gender identity disease Diseases 0.000 description 2
• 208000015891 sexual disease Diseases 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 201000009890 sinusitis Diseases 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 230000002195 synergetic effect Effects 0.000 description 2
• 208000006379 syphilis Diseases 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 229940120982 tarceva Drugs 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 230000002103 transcriptional effect Effects 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• 230000005748 tumor development Effects 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 239000000225 tumor suppressor protein Substances 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 150000003673 urethanes Chemical class 0.000 description 2
• 201000005112 urinary bladder cancer Diseases 0.000 description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
• SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
• 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
• JDHDUXCYWLIZJN-UHFFFAOYSA-N 1-(4-chlorophenyl)-9H-fluorene Chemical compound ClC1=CC=C(C=C1)C1=CC=CC=2C3=CC=CC=C3CC12 JDHDUXCYWLIZJN-UHFFFAOYSA-N 0.000 description 1
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
• KVGOXGQSTGQXDD-UHFFFAOYSA-N 1-decane-sulfonic-acid Chemical compound CCCCCCCCCCS(O)(=O)=O KVGOXGQSTGQXDD-UHFFFAOYSA-N 0.000 description 1
• 125000006039 1-hexenyl group Chemical group 0.000 description 1
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
• 125000006023 1-pentenyl group Chemical group 0.000 description 1
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
• VVZRKVYGKNFTRR-UHFFFAOYSA-N 12h-benzo[a]xanthene Chemical compound C1=CC=CC2=C3CC4=CC=CC=C4OC3=CC=C21 VVZRKVYGKNFTRR-UHFFFAOYSA-N 0.000 description 1
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
• YHIKXGASRRAEIA-UHFFFAOYSA-N 1h-1,2,4-triazol-5-ylcarbamic acid Chemical compound OC(=O)NC1=NC=NN1 YHIKXGASRRAEIA-UHFFFAOYSA-N 0.000 description 1
• PWBKJGAYFKBTMD-UHFFFAOYSA-N 1h-1,2,4-triazol-5-ylurea Chemical compound NC(=O)NC1=NC=NN1 PWBKJGAYFKBTMD-UHFFFAOYSA-N 0.000 description 1
• 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical class CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
• 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
• CYZIPMMNONORGD-UHFFFAOYSA-M 2-dodecylhexadecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCC(C[N+](C)(C)C)CCCCCCCCCCCC CYZIPMMNONORGD-UHFFFAOYSA-M 0.000 description 1
• 125000006040 2-hexenyl group Chemical group 0.000 description 1
• 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
• 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000005916 2-methylpentyl group Chemical group 0.000 description 1
• 125000006024 2-pentenyl group Chemical group 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000006041 3-hexenyl group Chemical group 0.000 description 1
• USCSRAJGJYMJFZ-UHFFFAOYSA-N 3-methyl-1-butyne Chemical compound CC(C)C#C USCSRAJGJYMJFZ-UHFFFAOYSA-N 0.000 description 1
• 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000005917 3-methylpentyl group Chemical group 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
• LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 101150019464 ARAF gene Proteins 0.000 description 1
• 206010060954 Abdominal Hernia Diseases 0.000 description 1
• 241000922028 Acanthamoeba astronyxis Species 0.000 description 1
• 241000224423 Acanthamoeba castellanii Species 0.000 description 1
• 241000167877 Acanthamoeba culbertsoni Species 0.000 description 1
• 241000921991 Acanthamoeba hatchetti Species 0.000 description 1
• 241000224430 Acanthamoeba polyphaga Species 0.000 description 1
• 241001455958 Acanthamoeba rhysodes Species 0.000 description 1
• 208000010444 Acidosis Diseases 0.000 description 1
• 241000186046 Actinomyces Species 0.000 description 1
• 206010001257 Adenoviral conjunctivitis Diseases 0.000 description 1
• 241000178243 Aeshna serrata Species 0.000 description 1
• 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 241000223602 Alternaria alternata Species 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 102100038778 Amphiregulin Human genes 0.000 description 1
• 108010033760 Amphiregulin Proteins 0.000 description 1
• 206010002199 Anaphylactic shock Diseases 0.000 description 1
• 241000606646 Anaplasma Species 0.000 description 1
• 102100032187 Androgen receptor Human genes 0.000 description 1
• 201000003076 Angiosarcoma Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 241001237431 Anomala Species 0.000 description 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
• 240000005528 Arctium lappa Species 0.000 description 1
• 241000712891 Arenavirus Species 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 200000000007 Arterial disease Diseases 0.000 description 1
• 240000002900 Arthrospira platensis Species 0.000 description 1
• 235000016425 Arthrospira platensis Nutrition 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 241000228197 Aspergillus flavus Species 0.000 description 1
• 241001225321 Aspergillus fumigatus Species 0.000 description 1
• 241000351920 Aspergillus nidulans Species 0.000 description 1
• 241000228245 Aspergillus niger Species 0.000 description 1
• 241000203233 Aspergillus versicolor Species 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 208000023345 Autoimmune Diseases of the Nervous System Diseases 0.000 description 1
• 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
• 241000714235 Avian retrovirus Species 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 241000193738 Bacillus anthracis Species 0.000 description 1
• 241000606125 Bacteroides Species 0.000 description 1
• 241000934146 Balamuthia mandrillaris Species 0.000 description 1
• 208000023514 Barrett esophagus Diseases 0.000 description 1
• 206010044583 Bartonella Infections Diseases 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 208000035462 Biphenotypic Acute Leukemia Diseases 0.000 description 1
• 241000335423 Blastomyces Species 0.000 description 1
• 208000006386 Bone Resorption Diseases 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 206010006002 Bone pain Diseases 0.000 description 1
• 241000588832 Bordetella pertussis Species 0.000 description 1
• 241000589968 Borrelia Species 0.000 description 1
• 241000180135 Borrelia recurrentis Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 235000000287 Brettanomyces bruxellensis Nutrition 0.000 description 1
• 241000722860 Brettanomyces naardenensis Species 0.000 description 1
• 206010006417 Bronchial carcinoma Diseases 0.000 description 1
• 241000589562 Brucella Species 0.000 description 1
• 210000003771 C cell Anatomy 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• 108091007381 CBL proteins Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000589876 Campylobacter Species 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 241000512906 Candida solani Species 0.000 description 1
• 241001123652 Candida versatilis Species 0.000 description 1
• 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 208000003732 Cat-scratch disease Diseases 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 241001660259 Cereus <cactus> Species 0.000 description 1
• 229910052684 Cerium Inorganic materials 0.000 description 1
• 208000009043 Chemical Burns Diseases 0.000 description 1
• 201000006082 Chickenpox Diseases 0.000 description 1
• 241000606161 Chlamydia Species 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 206010008631 Cholera Diseases 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 208000002691 Choroiditis Diseases 0.000 description 1
• 241000193403 Clostridium Species 0.000 description 1
• 241000193468 Clostridium perfringens Species 0.000 description 1
• 241000224483 Coccidia Species 0.000 description 1
• 241000223203 Coccidioides Species 0.000 description 1
• 241000223205 Coccidioides immitis Species 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• 206010055665 Corneal neovascularisation Diseases 0.000 description 1
• OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
• 241001125840 Coryphaenidae Species 0.000 description 1
• 241000709687 Coxsackievirus Species 0.000 description 1
• 206010011469 Crying Diseases 0.000 description 1
• 201000007336 Cryptococcosis Diseases 0.000 description 1
• 241000221204 Cryptococcus neoformans Species 0.000 description 1
• 241000223936 Cryptosporidium parvum Species 0.000 description 1
• 235000003392 Curcuma domestica Nutrition 0.000 description 1
• 244000008991 Curcuma longa Species 0.000 description 1
• 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
• 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
• 102000018832 Cytochromes Human genes 0.000 description 1
• 108010052832 Cytochromes Proteins 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• 102000003915 DNA Topoisomerases Human genes 0.000 description 1
• 108090000323 DNA Topoisomerases Proteins 0.000 description 1
• 230000004543 DNA replication Effects 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical class CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 208000001490 Dengue Diseases 0.000 description 1
• 206010012310 Dengue fever Diseases 0.000 description 1
• 241000725619 Dengue virus Species 0.000 description 1
• 206010012434 Dermatitis allergic Diseases 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
• 206010013774 Dry eye Diseases 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 101150029707 ERBB2 gene Proteins 0.000 description 1
• 208000030820 Ebola disease Diseases 0.000 description 1
• 241001115402 Ebolavirus Species 0.000 description 1
• 241000223932 Eimeria tenella Species 0.000 description 1
• 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
• 206010014612 Encephalitis viral Diseases 0.000 description 1
• 208000010334 End Stage Liver Disease Diseases 0.000 description 1
• 102100039328 Endoplasmin Human genes 0.000 description 1
• 241000224432 Entamoeba histolytica Species 0.000 description 1
• 241000709661 Enterovirus Species 0.000 description 1
• 241000991587 Enterovirus C Species 0.000 description 1
• 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 241001480036 Epidermophyton floccosum Species 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 208000007985 Erythema Infectiosum Diseases 0.000 description 1
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 208000027776 Extrapyramidal disease Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 241000192125 Firmicutes Species 0.000 description 1
• 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 230000010190 G1 phase Effects 0.000 description 1
• 241000531123 GB virus C Species 0.000 description 1
• IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 208000007882 Gastritis Diseases 0.000 description 1
• 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 241000224466 Giardia Species 0.000 description 1
• 241000224467 Giardia intestinalis Species 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 102000005133 Glutamate 5-kinase Human genes 0.000 description 1
• 108700023479 Glutamate 5-kinases Proteins 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 108030001320 Glutamine kinases Proteins 0.000 description 1
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 206010018498 Goitre Diseases 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 206010018691 Granuloma Diseases 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 241000606768 Haemophilus influenzae Species 0.000 description 1
• 239000012981 Hank's balanced salt solution Substances 0.000 description 1
• 241001149669 Hanseniaspora Species 0.000 description 1
• 241001149671 Hanseniaspora uvarum Species 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 101710113864 Heat shock protein 90 Proteins 0.000 description 1
• 241000589989 Helicobacter Species 0.000 description 1
• 241000590002 Helicobacter pylori Species 0.000 description 1
• 208000001258 Hemangiosarcoma Diseases 0.000 description 1
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
• 241000711549 Hepacivirus C Species 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 208000005331 Hepatitis D Diseases 0.000 description 1
• 206010019773 Hepatitis G Diseases 0.000 description 1
• 208000037262 Hepatitis delta Diseases 0.000 description 1
• 241000724709 Hepatitis delta virus Species 0.000 description 1
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
• 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
• 102220553472 Hepatocyte growth factor receptor_Y1230H_mutation Human genes 0.000 description 1
• 241000709721 Hepatovirus A Species 0.000 description 1
• 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
• 208000027927 Hereditary papillary renal cell carcinoma Diseases 0.000 description 1
• 208000004898 Herpes Labialis Diseases 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 208000007514 Herpes zoster Diseases 0.000 description 1
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 241000228404 Histoplasma capsulatum Species 0.000 description 1
• 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
• 101000763352 Homo sapiens Heat shock protein 75 kDa, mitochondrial Proteins 0.000 description 1
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
• 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
• 101100291010 Homo sapiens MET gene Proteins 0.000 description 1
• 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
• 101000616502 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Proteins 0.000 description 1
• 101000825399 Homo sapiens SHC-transforming protein 1 Proteins 0.000 description 1
• 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
• 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
• 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
• 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
• 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
• 241000829111 Human polyomavirus 1 Species 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
• 206010020850 Hyperthyroidism Diseases 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• 206010062717 Increased upper airway secretion Diseases 0.000 description 1
• 206010061217 Infestation Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 206010022714 Intestinal ulcer Diseases 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 201000005807 Japanese encephalitis Diseases 0.000 description 1
• 235000010254 Jasminum officinale Nutrition 0.000 description 1
• 240000005385 Jasminum sambac Species 0.000 description 1
• 208000002260 Keloid Diseases 0.000 description 1
• 206010023330 Keloid scar Diseases 0.000 description 1
• 108010076876 Keratins Proteins 0.000 description 1
• 102000011782 Keratins Human genes 0.000 description 1
• 241000588747 Klebsiella pneumoniae Species 0.000 description 1
• 244000285963 Kluyveromyces fragilis Species 0.000 description 1
• 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
• 241001138401 Kluyveromyces lactis Species 0.000 description 1
• 241001661539 Kregervanrija fluxuum Species 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
• 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
• 201000008197 Laryngitis Diseases 0.000 description 1
• 241000589248 Legionella Species 0.000 description 1
• 208000007764 Legionnaires' Disease Diseases 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 241000222724 Leishmania amazonensis Species 0.000 description 1
• 241000178949 Leishmania chagasi Species 0.000 description 1
• 241000222727 Leishmania donovani Species 0.000 description 1
• 241000222697 Leishmania infantum Species 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• 241000589902 Leptospira Species 0.000 description 1
• 241000780134 Leptospira venezuelensis Species 0.000 description 1
• 206010024264 Lethargy Diseases 0.000 description 1
• 241000186779 Listeria monocytogenes Species 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 206010025219 Lymphangioma Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 241000711828 Lyssavirus Species 0.000 description 1
• 201000003791 MALT lymphoma Diseases 0.000 description 1
• 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
• 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
• 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
• 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
• 206010025412 Macular dystrophy congenital Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 101150024075 Mapk1 gene Proteins 0.000 description 1
• 208000000932 Marburg Virus Disease Diseases 0.000 description 1
• 201000011013 Marburg hemorrhagic fever Diseases 0.000 description 1
• 241001115401 Marburgvirus Species 0.000 description 1
• 206010026865 Mass Diseases 0.000 description 1
• 241000712079 Measles morbillivirus Species 0.000 description 1
• 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 241000893980 Microsporum canis Species 0.000 description 1
• 208000024599 Mooren ulcer Diseases 0.000 description 1
• 241000588655 Moraxella catarrhalis Species 0.000 description 1
• 241000712045 Morbillivirus Species 0.000 description 1
• 241000235395 Mucor Species 0.000 description 1
• 241000711386 Mumps virus Species 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
• 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
• 208000023178 Musculoskeletal disease Diseases 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 241000545499 Mycobacterium avium-intracellulare Species 0.000 description 1
• 241000186362 Mycobacterium leprae Species 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• 241000204031 Mycoplasma Species 0.000 description 1
• 208000003926 Myelitis Diseases 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
• XSXAMSFKGRBSAB-UHFFFAOYSA-N NN.NC(N)=N Chemical compound NN.NC(N)=N XSXAMSFKGRBSAB-UHFFFAOYSA-N 0.000 description 1
• 241000224438 Naegleria fowleri Species 0.000 description 1
• 208000000592 Nasal Polyps Diseases 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 241000588653 Neisseria Species 0.000 description 1
• 241000588650 Neisseria meningitidis Species 0.000 description 1
• 201000009053 Neurodermatitis Diseases 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• 206010029350 Neurotoxicity Diseases 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 241000187654 Nocardia Species 0.000 description 1
• 108010025568 Nucleophosmin Proteins 0.000 description 1
• BTKYWYHRXHZPHU-UHFFFAOYSA-N OCCN.CNNC.NN Chemical compound OCCN.CNNC.NN BTKYWYHRXHZPHU-UHFFFAOYSA-N 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 241000243985 Onchocerca volvulus Species 0.000 description 1
• 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 1
• 206010067152 Oral herpes Diseases 0.000 description 1
• 241000150452 Orthohantavirus Species 0.000 description 1
• 208000010191 Osteitis Deformans Diseases 0.000 description 1
• 101710160107 Outer membrane protein A Proteins 0.000 description 1
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
• 108091008606 PDGF receptors Proteins 0.000 description 1
• 108091007960 PI3Ks Proteins 0.000 description 1
• 208000027868 Paget disease Diseases 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 240000004371 Panax ginseng Species 0.000 description 1
• 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
• 235000003140 Panax quinquefolius Nutrition 0.000 description 1
• 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
• 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
• 208000031481 Pathologic Constriction Diseases 0.000 description 1
• 101710161551 Pectate lyase 3 Proteins 0.000 description 1
• 206010034650 Peritoneal adhesions Diseases 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 241000713137 Phlebovirus Species 0.000 description 1
• 102100021797 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Human genes 0.000 description 1
• 101710124951 Phospholipase C Proteins 0.000 description 1
• 240000009188 Phyllostachys vivax Species 0.000 description 1
• 241000521553 Pichia fermentans Species 0.000 description 1
• 241000235645 Pichia kudriavzevii Species 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 241000101040 Pityriasis Species 0.000 description 1
• 241000224017 Plasmodium berghei Species 0.000 description 1
• 241000223960 Plasmodium falciparum Species 0.000 description 1
• 241000223821 Plasmodium malariae Species 0.000 description 1
• 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
• 241000223810 Plasmodium vivax Species 0.000 description 1
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
• 208000035109 Pneumococcal Infections Diseases 0.000 description 1
• 241000233870 Pneumocystis Species 0.000 description 1
• 241000233872 Pneumocystis carinii Species 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 208000005374 Poisoning Diseases 0.000 description 1
• 208000008601 Polycythemia Diseases 0.000 description 1
• 208000003971 Posterior uveitis Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 102000029797 Prion Human genes 0.000 description 1
• 108091000054 Prion Proteins 0.000 description 1
• 101710179609 Probable pectin lyase C Proteins 0.000 description 1
• 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
• 206010036877 Prolonged Pregnancy Diseases 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• 241000588769 Proteus <enterobacteria> Species 0.000 description 1
• 102000005663 Proto-Oncogene Proteins c-abl Human genes 0.000 description 1
• 108010045292 Proto-Oncogene Proteins c-abl Proteins 0.000 description 1
• 102000055251 Proto-Oncogene Proteins c-cbl Human genes 0.000 description 1
• 241000125945 Protoparvovirus Species 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 241001621636 Pterygia Species 0.000 description 1
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
• 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
• 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
• 206010037742 Rabies Diseases 0.000 description 1
• 241000711798 Rabies lyssavirus Species 0.000 description 1
• 241000218206 Ranunculus Species 0.000 description 1
• 208000034541 Rare lymphatic malformation Diseases 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
• 241000702263 Reovirus sp. Species 0.000 description 1
• 241000725643 Respiratory syncytial virus Species 0.000 description 1
• 108091027981 Response element Proteins 0.000 description 1
• 206010038848 Retinal detachment Diseases 0.000 description 1
• 206010038910 Retinitis Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 206010038934 Retinopathy proliferative Diseases 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 241000606701 Rickettsia Species 0.000 description 1
• 208000000705 Rift Valley Fever Diseases 0.000 description 1
• 241000713124 Rift Valley fever virus Species 0.000 description 1
• 239000008156 Ringer's lactate solution Substances 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 241000710799 Rubella virus Species 0.000 description 1
• 102100022340 SHC-transforming protein 1 Human genes 0.000 description 1
• 241000983742 Saccharina Species 0.000 description 1
• 241000582914 Saccharomyces uvarum Species 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 241001439627 Schistostoma Species 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• 206010039705 Scleritis Diseases 0.000 description 1
• 241000239226 Scorpiones Species 0.000 description 1
• 102000009203 Sema domains Human genes 0.000 description 1
• 108050000099 Sema domains Proteins 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 201000001880 Sexual dysfunction Diseases 0.000 description 1
• 241000607768 Shigella Species 0.000 description 1
• 206010049771 Shock haemorrhagic Diseases 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010040829 Skin discolouration Diseases 0.000 description 1
• 206010041235 Snoring Diseases 0.000 description 1
• 208000005392 Spasm Diseases 0.000 description 1
• 241000589970 Spirochaetales Species 0.000 description 1
• 208000006045 Spondylarthropathies Diseases 0.000 description 1
• 241001149962 Sporothrix Species 0.000 description 1
• 102000007451 Steroid Receptors Human genes 0.000 description 1
• 208000007107 Stomach Ulcer Diseases 0.000 description 1
• 206010061372 Streptococcal infection Diseases 0.000 description 1
• 241000194017 Streptococcus Species 0.000 description 1
• 241000193998 Streptococcus pneumoniae Species 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
• 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
• 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 1
• 241001523006 Talaromyces marneffei Species 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 208000025371 Taste disease Diseases 0.000 description 1
• 206010043189 Telangiectasia Diseases 0.000 description 1
• 208000018656 Terrien marginal degeneration Diseases 0.000 description 1
• 206010043376 Tetanus Diseases 0.000 description 1
• 208000003217 Tetany Diseases 0.000 description 1
• 241000223777 Theileria Species 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 101710183280 Topoisomerase Proteins 0.000 description 1
• 241000235006 Torulaspora Species 0.000 description 1
• 206010044221 Toxic encephalopathy Diseases 0.000 description 1
• 241000223996 Toxoplasma Species 0.000 description 1
• 201000005485 Toxoplasmosis Diseases 0.000 description 1
• 101710204707 Transforming growth factor-beta receptor-associated protein 1 Proteins 0.000 description 1
• 241000589884 Treponema pallidum Species 0.000 description 1
• 241000243774 Trichinella Species 0.000 description 1
• 241000224526 Trichomonas Species 0.000 description 1
• 241000224527 Trichomonas vaginalis Species 0.000 description 1
• 241001459572 Trichophyton interdigitale Species 0.000 description 1
• 241000223229 Trichophyton rubrum Species 0.000 description 1
• 241000223230 Trichosporon Species 0.000 description 1
• 235000021307 Triticum Nutrition 0.000 description 1
• 244000098338 Triticum aestivum Species 0.000 description 1
• 241000223104 Trypanosoma Species 0.000 description 1
• 241001442397 Trypanosoma brucei rhodesiense Species 0.000 description 1
• 241000223109 Trypanosoma cruzi Species 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
• 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
• 206010064996 Ulcerative keratitis Diseases 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 206010046798 Uterine leiomyoma Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 206010046980 Varicella Diseases 0.000 description 1
• 208000009443 Vascular Malformations Diseases 0.000 description 1
• 208000024248 Vascular System injury Diseases 0.000 description 1
• 208000012339 Vascular injury Diseases 0.000 description 1
• 206010053648 Vascular occlusion Diseases 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 208000014070 Vestibular schwannoma Diseases 0.000 description 1
• 241000607598 Vibrio Species 0.000 description 1
• 241000607626 Vibrio cholerae Species 0.000 description 1
• 206010047505 Visceral leishmaniasis Diseases 0.000 description 1
• 241000219094 Vitaceae Species 0.000 description 1
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
• 206010047663 Vitritis Diseases 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 238000004097 X-ray Buerger Methods 0.000 description 1
• 241000235015 Yarrowia lipolytica Species 0.000 description 1
• 241000710772 Yellow fever virus Species 0.000 description 1
• 241000235033 Zygosaccharomyces rouxii Species 0.000 description 1
• BKUGOELSVSCNTB-UHFFFAOYSA-N [5-(2,4-dihydroxy-5-methoxyphenyl)-4-naphthalen-1-yl-1,2,4-triazol-3-yl]urea Chemical compound C1=C(O)C(OC)=CC(C=2N(C(NC(N)=O)=NN=2)C=2C3=CC=CC=C3C=CC=2)=C1O BKUGOELSVSCNTB-UHFFFAOYSA-N 0.000 description 1
• 241000222126 [Candida] glabrata Species 0.000 description 1
• 241000191335 [Candida] intermedia Species 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 230000007950 acidosis Effects 0.000 description 1
• 208000026545 acidosis disease Diseases 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 238000001467 acupuncture Methods 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 208000036676 acute undifferentiated leukemia Diseases 0.000 description 1
• 125000002015 acyclic group Chemical group 0.000 description 1
• 230000002730 additional effect Effects 0.000 description 1
• 239000000809 air pollutant Substances 0.000 description 1
• 231100001243 air pollutant Toxicity 0.000 description 1
• 239000013572 airborne allergen Substances 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 208000030961 allergic reaction Diseases 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 125000006242 amine protecting group Chemical group 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 108010080146 androgen receptors Proteins 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 208000000252 angiomatosis Diseases 0.000 description 1
• 230000002547 anomalous effect Effects 0.000 description 1
• PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
• 150000004056 anthraquinones Chemical class 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• 230000004872 arterial blood pressure Effects 0.000 description 1
• 208000021328 arterial occlusion Diseases 0.000 description 1
• 206010003230 arteritis Diseases 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 229940091771 aspergillus fumigatus Drugs 0.000 description 1
• 208000035362 autoimmune disorder of the nervous system Diseases 0.000 description 1
• 201000004339 autoimmune neuropathy Diseases 0.000 description 1
• 230000006472 autoimmune response Effects 0.000 description 1
• 201000004982 autoimmune uveitis Diseases 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 229940065181 bacillus anthracis Drugs 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 206010004145 bartonellosis Diseases 0.000 description 1
• 230000003796 beauty Effects 0.000 description 1
• 235000013405 beer Nutrition 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• 230000000035 biogenic effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 229910052797 bismuth Inorganic materials 0.000 description 1
• JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
• 208000034158 bleeding Diseases 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 208000002352 blister Diseases 0.000 description 1
• 208000024753 bloody sputum Diseases 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 230000024279 bone resorption Effects 0.000 description 1
• 101150048834 braF gene Proteins 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 125000005997 bromomethyl group Chemical group 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
• 229940095731 candida albicans Drugs 0.000 description 1
• 208000032343 candida glabrata infection Diseases 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• 210000001715 carotid artery Anatomy 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
• 235000013351 cheese Nutrition 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 150000001805 chlorine compounds Chemical class 0.000 description 1
• 229930002875 chlorophyll Natural products 0.000 description 1
• 235000019804 chlorophyll Nutrition 0.000 description 1
• ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000024321 chromosome segregation Effects 0.000 description 1
• 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
• 208000011444 chronic liver failure Diseases 0.000 description 1
• 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 1
• 210000004240 ciliary body Anatomy 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 208000018631 connective tissue disease Diseases 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 206010011005 corneal dystrophy Diseases 0.000 description 1
• 201000000159 corneal neovascularization Diseases 0.000 description 1
• 108091008723 corticosteroid receptors Proteins 0.000 description 1
• OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
• 229960004544 cortisone Drugs 0.000 description 1
• 235000003373 curcuma longa Nutrition 0.000 description 1
• 150000001924 cycloalkanes Chemical class 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 208000031513 cyst Diseases 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 230000002354 daily effect Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 231100000517 death Toxicity 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 208000025729 dengue disease Diseases 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 208000024558 digestive system cancer Diseases 0.000 description 1
• 150000004683 dihydrates Chemical class 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
• 125000000597 dioxinyl group Chemical group 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• 238000002845 discoloration Methods 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 206010013781 dry mouth Diseases 0.000 description 1
• 210000000959 ear middle Anatomy 0.000 description 1
• 230000008143 early embryonic development Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
• 210000003372 endocrine gland Anatomy 0.000 description 1
• 206010014801 endophthalmitis Diseases 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 231100000249 enterotoxic Toxicity 0.000 description 1
• 230000002242 enterotoxic effect Effects 0.000 description 1
• 230000029578 entry into host Effects 0.000 description 1
• 230000006353 environmental stress Effects 0.000 description 1
• 239000003256 environmental substance Substances 0.000 description 1
• 230000009088 enzymatic function Effects 0.000 description 1
• 208000021373 epidemic keratoconjunctivitis Diseases 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 230000008029 eradication Effects 0.000 description 1
• 231100000321 erythema Toxicity 0.000 description 1
• 201000005619 esophageal carcinoma Diseases 0.000 description 1
• PRWVVRDSBJSXQY-UHFFFAOYSA-N ethyl [2-ethyl-5-hydroxy-4-(4-naphthalen-2-yl-5-oxo-1H-1,2,4-triazol-3-yl)phenyl] carbonate Chemical compound OC1=C(C=C(C(=C1)OC(=O)OCC)CC)C1=NN=C(N1C1=CC2=CC=CC=C2C=C1)O PRWVVRDSBJSXQY-UHFFFAOYSA-N 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 208000024711 extrinsic asthma Diseases 0.000 description 1
• 210000004709 eyebrow Anatomy 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 206010049444 fibromatosis Diseases 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 229940050411 fumarate Drugs 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
• 210000005095 gastrointestinal system Anatomy 0.000 description 1
• 201000010231 gastrointestinal system cancer Diseases 0.000 description 1
• 229960002584 gefitinib Drugs 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 102000034356 gene-regulatory proteins Human genes 0.000 description 1
• 108091006104 gene-regulatory proteins Proteins 0.000 description 1
• 210000004392 genitalia Anatomy 0.000 description 1
• 231100000024 genotoxic Toxicity 0.000 description 1
• 230000001738 genotoxic effect Effects 0.000 description 1
• 229940114119 gentisate Drugs 0.000 description 1
• 235000008434 ginseng Nutrition 0.000 description 1
• 230000004313 glare Effects 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 239000000174 gluconic acid Substances 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 108010017007 glucose-regulated proteins Proteins 0.000 description 1
• 229940097042 glucuronate Drugs 0.000 description 1
• 229940097043 glucuronic acid Drugs 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
• 201000003872 goiter Diseases 0.000 description 1
• 210000002149 gonad Anatomy 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 235000021021 grapes Nutrition 0.000 description 1
• 101150098203 grb2 gene Proteins 0.000 description 1
• VNSFGLSIVSOPEC-UHFFFAOYSA-N guanidine;urea Chemical compound NC(N)=N.NC(N)=O VNSFGLSIVSOPEC-UHFFFAOYSA-N 0.000 description 1
• 150000002357 guanidines Chemical class 0.000 description 1
• 229940047650 haemophilus influenzae Drugs 0.000 description 1
• 210000004209 hair Anatomy 0.000 description 1
• 208000024963 hair loss Diseases 0.000 description 1
• 230000003676 hair loss Effects 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 230000003862 health status Effects 0.000 description 1
• 208000025750 heavy chain disease Diseases 0.000 description 1
• 229940037467 helicobacter pylori Drugs 0.000 description 1
• 201000002222 hemangioblastoma Diseases 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 230000009033 hematopoietic malignancy Effects 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 201000010284 hepatitis E Diseases 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 239000008241 heterogeneous mixture Substances 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 108091008039 hormone receptors Proteins 0.000 description 1
• 208000013653 hyalitis Diseases 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
• 208000009326 ileitis Diseases 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 231100000619 immunotoxicology Toxicity 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 229940060367 inert ingredients Drugs 0.000 description 1
• 208000037903 inflammatory enteropathy Diseases 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
• 229960000367 inositol Drugs 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000002085 irritant Substances 0.000 description 1
• 231100000021 irritant Toxicity 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 238000006317 isomerization reaction Methods 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 239000010977 jade Substances 0.000 description 1
• 210000001117 keloid Anatomy 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 201000010260 leiomyoma Diseases 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 208000002741 leukoplakia Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 229920006008 lipopolysaccharide Polymers 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 108010070324 lumbrokinase Proteins 0.000 description 1
• 201000005249 lung adenocarcinoma Diseases 0.000 description 1
• 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 230000010311 mammalian development Effects 0.000 description 1
• 208000027202 mammary Paget disease Diseases 0.000 description 1
• 201000006512 mast cell neoplasm Diseases 0.000 description 1
• 210000001595 mastoid Anatomy 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 235000012054 meals Nutrition 0.000 description 1
• 235000013372 meat Nutrition 0.000 description 1
• 238000010297 mechanical methods and process Methods 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 235000019656 metallic taste Nutrition 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
• 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 230000024799 morphogenesis of a branching structure Effects 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 230000036457 multidrug resistance Effects 0.000 description 1
• 208000013465 muscle pain Diseases 0.000 description 1
• 230000000869 mutational effect Effects 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• 208000001491 myopia Diseases 0.000 description 1
• 230000004379 myopia Effects 0.000 description 1
• 210000001087 myotubule Anatomy 0.000 description 1
• 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 208000025189 neoplasm of testis Diseases 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 201000003142 neovascular glaucoma Diseases 0.000 description 1
• 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
• 231100000417 nephrotoxicity Toxicity 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 231100000228 neurotoxicity Toxicity 0.000 description 1
• 230000007135 neurotoxicity Effects 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 125000006574 non-aromatic ring group Chemical group 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 108091008569 nuclear steroid hormone receptors Proteins 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 210000004287 null lymphocyte Anatomy 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 235000008935 nutritious Nutrition 0.000 description 1
• 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 208000002042 onchocerciasis Diseases 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 230000005305 organ development Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000011164 ossification Effects 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 230000002188 osteogenic effect Effects 0.000 description 1
• 208000025661 ovarian cyst Diseases 0.000 description 1
• 150000003891 oxalate salts Chemical class 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 108700009251 p80(NPM-ALK) Proteins 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 229940014662 pantothenate Drugs 0.000 description 1
• 239000011713 pantothenic acid Substances 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
• 201000010198 papillary carcinoma Diseases 0.000 description 1
• 208000003154 papilloma Diseases 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 102000045222 parkin Human genes 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000009589 pathological growth Effects 0.000 description 1
• 201000002689 pediatric hepatocellular carcinoma Diseases 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 201000001245 periodontitis Diseases 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 208000023974 pharynx neoplasm Diseases 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 208000026435 phlegm Diseases 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 229940118768 plasmodium malariae Drugs 0.000 description 1
• 201000000317 pneumocystosis Diseases 0.000 description 1
• 231100000572 poisoning Toxicity 0.000 description 1
• 230000000607 poisoning effect Effects 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
• 230000016833 positive regulation of signal transduction Effects 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000001686 pro-survival effect Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
• 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 230000012846 protein folding Effects 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000004063 proteosomal degradation Effects 0.000 description 1
• 208000028172 protozoa infectious disease Diseases 0.000 description 1
• 210000001147 pulmonary artery Anatomy 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 108010077182 raf Kinases Proteins 0.000 description 1
• 102000009929 raf Kinases Human genes 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 210000001350 reed-sternberg cell Anatomy 0.000 description 1
• 230000031539 regulation of cell division Effects 0.000 description 1
• 230000014493 regulation of gene expression Effects 0.000 description 1
• 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 230000004264 retinal detachment Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 206010039083 rhinitis Diseases 0.000 description 1
• 238000012502 risk assessment Methods 0.000 description 1
• 102220198013 rs1057519824 Human genes 0.000 description 1
• 102220197908 rs121913244 Human genes 0.000 description 1
• 102220004853 rs121913246 Human genes 0.000 description 1
• 102220067223 rs121913247 Human genes 0.000 description 1
• 102200055453 rs121913340 Human genes 0.000 description 1
• 102200055517 rs121913348 Human genes 0.000 description 1
• 102200055451 rs121913361 Human genes 0.000 description 1
• 102200055463 rs121913369 Human genes 0.000 description 1
• 102220004849 rs121913668 Human genes 0.000 description 1
• 102220004851 rs121913670 Human genes 0.000 description 1
• 102220004854 rs121913673 Human genes 0.000 description 1
• 102220004765 rs121913675 Human genes 0.000 description 1
• 102220004856 rs121913676 Human genes 0.000 description 1
• 102220004857 rs121913677 Human genes 0.000 description 1
• 102220066714 rs766049601 Human genes 0.000 description 1
• 102220216833 rs768678989 Human genes 0.000 description 1
• 102220059662 rs786202724 Human genes 0.000 description 1
• 229960002181 saccharomyces boulardii Drugs 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229930182490 saponin Natural products 0.000 description 1
• 150000007949 saponins Chemical class 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000001235 sensitizing effect Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 231100000872 sexual dysfunction Toxicity 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 201000006476 shipyard eye Diseases 0.000 description 1
• 208000007056 sickle cell anemia Diseases 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 230000037370 skin discoloration Effects 0.000 description 1
• 239000000779 smoke Substances 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 201000005671 spondyloarthropathy Diseases 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 238000011476 stem cell transplantation Methods 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 208000037804 stenosis Diseases 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 102000005969 steroid hormone receptors Human genes 0.000 description 1
• 108020003113 steroid hormone receptors Proteins 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 210000000434 stratum corneum Anatomy 0.000 description 1
• 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• 229940086735 succinate Drugs 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 230000004654 survival pathway Effects 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 201000008759 sweat gland cancer Diseases 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 201000004595 synovitis Diseases 0.000 description 1
• 201000008753 synovium neoplasm Diseases 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 229940066765 systemic antihistamines substituted ethylene diamines Drugs 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 239000001648 tannin Substances 0.000 description 1
• 235000018553 tannin Nutrition 0.000 description 1
• 229920001864 tannin Polymers 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• 150000004772 tellurides Chemical class 0.000 description 1
• 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 150000004685 tetrahydrates Chemical class 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• AGGKEGLBGGJEBZ-UHFFFAOYSA-N tetramethylenedisulfotetramine Chemical compound C1N(S2(=O)=O)CN3S(=O)(=O)N1CN2C3 AGGKEGLBGGJEBZ-UHFFFAOYSA-N 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000005033 thiopyranyl group Chemical group 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
• 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 1
• 229960002312 tolazoline Drugs 0.000 description 1
• 206010044008 tonsillitis Diseases 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 125000005270 trialkylamine group Chemical group 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 150000004684 trihydrates Chemical class 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 235000013976 turmeric Nutrition 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 125000005289 uranyl group Chemical group 0.000 description 1
• 208000037965 uterine sarcoma Diseases 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 208000021331 vascular occlusion disease Diseases 0.000 description 1
• 239000004066 vascular targeting agent Substances 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 201000009371 venous hemangioma Diseases 0.000 description 1
• 229940118696 vibrio cholerae Drugs 0.000 description 1
• 201000002498 viral encephalitis Diseases 0.000 description 1
• 206010047470 viral myocarditis Diseases 0.000 description 1
• 235000019155 vitamin A Nutrition 0.000 description 1
• 239000011719 vitamin A Substances 0.000 description 1
• 229940045997 vitamin a Drugs 0.000 description 1
• 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 210000004885 white matter Anatomy 0.000 description 1
• 238000013389 whole blood assay Methods 0.000 description 1
• 229940051021 yellow-fever virus Drugs 0.000 description 1